Deutsche Bank AG Takes Position in Bicara Therapeutics Inc. $BCAX

Key Points

• Deutsche Bank acquired 144,010 shares of Bicara Therapeutics in the second quarter, valued at approximately $4.3 million and representing about 0.22% of the company. Several other institutional investors also increased or initiated positions.
• Bicara shares opened at $24.58, with a market capitalization of approximately $1.63 billion. The company reported quarterly EPS of negative $0.82, in line with analyst expectations, while full-year estimates call for a loss of $3.45 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $32.64. However, insiders have sold 108,000 shares worth roughly $3.1 million over the past 90 days.

Deutsche Bank AG acquired a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 144,010 shares of the company's stock, valued at approximately $4,276,000. Deutsche Bank AG owned approximately 0.22% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in BCAX. Legal & General Group Plc boosted its position in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after acquiring an additional 1,233 shares during the period. Tower Research Capital LLC TRC increased its holdings in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after acquiring an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics during the 4th quarter worth approximately $45,000. Larson Financial Group LLC lifted its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after purchasing an additional 4,585 shares in the last quarter.

Bicara Therapeutics Stock Up 4.2%

Bicara Therapeutics stock opened at $24.58 on Wednesday. The firm has a fifty day simple moving average of $26.64 and a two-hundred day simple moving average of $22.23. Bicara Therapeutics Inc. has a twelve month low of $10.30 and a twelve month high of $30.99. The company has a market capitalization of $1.63 billion, a PE ratio of -7.93 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.82). As a group, equities analysts expect that Bicara Therapeutics Inc. will post -3.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BCAX. Wall Street Zen upgraded Bicara Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, May 24th. Wells Fargo & Company boosted their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 12th. Guggenheim initiated coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They issued a "buy" rating and a $42.00 target price on the stock. Morgan Stanley boosted their price target on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 11th. Finally, Citigroup restated a "market outperform" rating on shares of Bicara Therapeutics in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $32.64.

Insiders Place Their Bets

In related news, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company's stock, valued at $10,133,012.96. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the company's stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the sale, the chief financial officer owned 129,855 shares of the company's stock, valued at $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,000 shares of company stock valued at $3,079,236 in the last ninety days. Company insiders own 13.80% of the company's stock.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source